The prognosis for patients with idiopathic dilated cardiomyopathy (DCM) is poor, although clinical features are variable. Prediction of outcome has been difficult in individual patients based on laboratory data. In some patients with DCM, myocardial damage secondary to viral or immune-mediated myocardial inflammation may persist. To objectively assess inflammation, we measured plasma concentrations of C-reactive protein (CRP) in 188 patients with idiopathic DCM over 5–8 years. All had dyspnea and fatigue at rest; all patients had a left ventricular ejection fraction less than 40% by echocardiography or by contrast or radionuclide ventriculography. We divided these patients into two groups: patients dying within 5 years following admission (n = 49) and the remainder surviving for at least 5 years (n = 139). CRP concentrations in the patients dying early were significantly higher than in the long-term survivors (1.05 ± 1.37 vs. 0.49 ± 1.04 mg/dl, p < 0.05). Sixty-two percent of the patients with CRP>1.0 died within 5 years. In addition to other laboratory tests including electrocardiography and echocardiography, routine CRP measurements proved to be valuable for identifying high-risk patients who require special treatment strategies.

1.
Katz AM: Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100–110.
2.
Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe heart failure. Circulation 1986;73:257–267.
3.
Cohn JN, Levine TB, Olivani MT, Ganberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819–825.
4.
Clerand JG, Dargie HJ, Ford I: Mortality in heart failure. Clinical variables of prognostic value. Br Heart J 1987;58:572–582.
5.
Pepys MB: The actue phase response and C-reactive protein; in Weatherall DJ, Leingham JGG, Warrell DA (eds): Oxford Textbook of Medicine, ed 3. Oxford, Oxford University Press, 1995, pp 1527–1533.
6.
Shine B, de Beer FC, Pepys MB: Solid phase radioimmunoassays for C-reactive protein. Clin Chim Acta 1981;117:13–23.
7.
Miyatake K, Okamoto M, Kinoshita N, Izumi S, Owa M, Takao S, Sakakibara H, Nimura Y: Clinical applications of a new type of real-time two-dimensional Doppler flow imaging system. Am J Cardiol 1984;54:857–868.
8.
Sahn OJ, DcMaria AN, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurement. Circulation 1978;58:1072–1083.
9.
Pietila K, Harmonien A, Teppo AM: Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med 1991;23:529–535.
10.
Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S: C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778–784.
11.
Kaneko K, Kanda T, Nakazato Y, Kobayashi I, Nagai R: Expression of interleukin-6 in myocardium and coronary arteries in patients with myocardial infarction. Res Commun Mol Pathol Pharmacol 1997;97:3–12.
12.
Limas CJ, Goldenberg IF, Limas C: Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy; Correlation with disease severity and cardiac antibodies. Circulation 1995;91:631–634.
13.
Matsumori A, Yamada T: Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561–566.
14.
O’Connell JB: The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Inst J 1987;14:268–275.
15.
Kanda T, Araki M, Nakano M, Imai S, Suzuki T, Kobayashi I: Chronic effect of losartan in a murine model of dilated cardiomyopathy: Comparison with captopril. J Pharmacol Exp Ther 1995;273:955–958.
16.
Ikram H, Williamson HG, Won M, Crozier IG, Wells EJ: The course of idiopathic dilated cardiomyopathy in New Zealand. Br Heart J 1987;57:521–527.
17.
Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B: Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564–570.
18.
Packer M, Leier CV: Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 1987;75:IV56–IV63.
19.
Wilson JR: Use of antiarrhythmic drugs in patients with heart fialure: Clinical efficacy, hemodynamic results, and relation to survival. Circulation 1987;75:IV64–IV63.
20.
Newmank TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Copper WH: Effects of captopril on survival in patients with heart failure. Am J Med 1988;84:140–144.
21.
Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525–531.
22.
Unverferth DV, Magorien RD, Moeschberger ML, Backer PB, Fetters JK, Leier CV: Factors influencing the one-year mortality of cardiomyopathy. Am J Cardiol 1984;54:147–152.
23.
Diaz RA, Obasohan A, Oakley CM: Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987;58:393–399.
24.
Romeo F, Pelliccia F, Cianfrocca C, Gallo P, Barilla F, Cristofani R: Determinants of end-stage idiopathic dilated cardiomyopathy: A multivariate analysis of 104 patients. Clin Cardiol 1989;12:387–392.
25.
Abramson SV, Burke JF, Kelly JJ, Kitchen JG, Dougherty MJ, Yih DF, McGreehin FC, Shuck JW, Phiambolis TP: Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Am Intern Med 1992;116:888–895.
26.
Miric M, Miskovic A, Brkic S, Vasiljevic J, Keserovic N, Pesic M: Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. FEMS Immunol Med Microbiol 1994;10:65–74.
27.
McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, Murali S, Feldman AM: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95:2476–2478.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.